Guruprasad Padur Aithal

Bsc MBBS MD DNB MRCP CCST PhD FRCP

Professor Guruprasad P. Aithal is the Professor of Hepatology and the Head of the Nottingham Digestive Diseases centre, University of Nottingham. He leads the Gastrointestinal and Liver Disorder Theme of National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre (BRC). He has over 150 publications with H index of 47 currently. His landmark study on warfarin pharmacogenetics (*Lancet 1999*) catalysed the field, leading the US Food and Drug administration (FDA) to recommend (2007 & 2010) genetic testing during warfarin dosing and its wider application in practice. He also led an international expert panel to establish phenotypic standardisation in drug-induced liver injury (DILI) (*Clin Pharmacol Ther. 2011*). He co-chaired international DILI consortia (iDILIC) to conduct a seminal genome-wide association studies identifying key associations with key polymorphisms in *HLA* and other genes with DILI (*Nat Genet.* 2009, Gastroenterology 2017).

Prof Aithal is the Deputy Director of the Medical research Council (MRC) Nottingham Molecular Pathology Node. He contributed critically to the evaluation of the Enhanced Liver Fibrosis panel (*Hepatology. 2008*, *Hepatology. 2013*), the only non-invasive marker set recommended for clinical use by National Institute for Health and Care Excellence, UK in the draft NICE guidance (2015) on NASH and cirrhosis. He also evaluated piogltazone (*Gastroenterology. 2008*) and liraglutide (*Lancet 2016*) in phase II trials to demonstrate efficacy in NASH.

Prof Aithal has led the development of fast, and inexpensive magnetic resonance imaging (MRI) method to estimate the degree of inflammation and fibrosis within the whole liver (*NMR Biomed. 2015*). Recently, he used this method to estimate portal pressure (*J Hepatol 2016*), showing that it correlates with hepatic venous pressure gradient measurements – the current gold standard but invasive and expensive test, only available in selected centres.